Integrated Omics of Metastatic Colorectal Cancer

Chen Li,Yi-Di Sun,Guan-Yu Yu,Jing-Ru Cui,Zheng Lou,Hang Zhang,Ya Huang,Chen-Guang Bai,Lu-Lu Deng,Peng Liu,Kuo Zheng,Yan-Hua Wang,Qin-Qin Wang,Qing-Run Li,Qing-Qing Wu,Qi Liu,Yu Shyr,Yi-Xue Li,Luo-Nan Chen,Jia-Rui Wu,Wei Zhang,Rong Zeng
DOI: https://doi.org/10.1016/j.ccell.2020.08.002
IF: 50.3
2020-11-01
Cancer Cell
Abstract:We integrate the genomics, proteomics, and phosphoproteomics of 480 clinical tissues from 146 patients in a Chinese colorectal cancer (CRC) cohort, among which 70 had metastatic CRC (mCRC). Proteomic profiling differentiates three CRC subtypes characterized by distinct clinical prognosis and molecular signatures. Proteomic and phosphoproteomic profiling of primary tumors alone successfully distinguishes cases with metastasis. Metastatic tissues exhibit high similarities with primary tumors at the genetic but not the proteomic level, and kinase network analysis reveals significant heterogeneity between primary colorectal tumors and their liver metastases. <em>In vivo</em> xenograft-based drug tests using 31 primary and metastatic tumors show personalized responses, which could also be predicted by kinase-substrate network analysis no matter whether tumors carry mutations in the drug-targeted genes. Our study provides a valuable resource for better understanding of mCRC and has potential for clinical application.
oncology,cell biology
What problem does this paper attempt to address?
The problems that this paper attempts to solve mainly focus on the multi - omics feature analysis of metastatic colorectal cancer (mCRC). Specifically, the research aims to reveal the heterogeneity of mCRC at the molecular level by integrating genomics, proteomics and phosphoproteomics data, and to explore how these features affect patients' prognosis and drug response. The following are the main research objectives of the paper: 1. **Reveal the molecular heterogeneity of mCRC**: Through large - scale proteogenomic research on 480 clinical tissue samples, the authors hope to identify different subtypes of mCRC, which have significant differences in clinical prognosis and molecular features. 2. **Distinguish between primary tumors and metastatic tumors**: Through proteomics and phosphoproteomics analysis, the research attempts to distinguish primary colorectal cancer from metastatic tumors, especially the differences at the proteome level, because the similarity at the genetic level is relatively high. 3. **Predict drug response**: Using kinase - substrate network analysis, the research aims to discover biomarkers that can accurately predict drug response, even if the tumor does not carry mutations in drug - target genes. 4. **Improve the selection of treatment strategies**: Ultimately, the goal of the research is to improve the selection of treatment strategies for patients without drug - targetable mutations, by providing personalized drug - testing models to help clinicians better select treatment options. Through these research objectives, the paper provides a deeper understanding of mCRC and provides valuable resources for clinical applications, which is helpful for achieving more precise and personalized cancer treatment.